Protagenic Therapeutics Inc.
04/07/2026 | Press release | Distributed by Public on 04/07/2026 04:02
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 31, 2026, the Board of Directors of Protagenic Therapeutics, Inc. (the "Company") notified Alexander Arrow, MD, the Company's Chief Financial Officer, that his employment with the Company will be terminated effective April 30, 2026.
Protagenic Therapeutics Inc. published this content on April 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 07, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]